A prospective non-randomised, multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies


Trial Overview and Summary
 Chief Investigator:  Professor Daniel Rea
 Sponsor:  University of Birmingham 
 Funder:  CRUK and BiSTC
 Disease Site:  Breast
 Trial Type:  Feasibility Study
 Status:  Open to recruitment
 UKCRN Study ID:  38071
 Open to New Sites?  Yes
 Recruitment Start Date:  May 2019
 Anticipated Recruitment End Date:  End of December 2023
 CRCTU Trial Management Team:  B Team
 Trial Email Address:

Trial Summary

A prospective non-randomised, single-arm, multicentre, feasibility study for a proposed future randomised phase III clinical trial. To determine whether patients with residual cancer can be identified by histological examination of multiple US-guided tumour bed core biopsies following dual-targeted neoadjuvant treatment for HER2-positive, ER-negative early primary breast cancer.

  • NOSTRA Trial Summary v3.0 29-Jan-2020

Trial Protocol (login required)

  • NOSTRA Protocol Version 3.0 29-Jan-2020 [pdf]

More Information